KR20200069582A - Nano fiber membrane for the diagnosis of urinary tract infection including two types of nanofibers and a method for manufacturing the same - Google Patents

Abstract

Disclosed is a nanofibrous membrane for the diagnosis of urinary tract infection, including irregularly arranged nanofibers, wherein the nanofibers include a first nanofiber comprising a first reagent and a second nanofiber comprising a second reagent, wherein the first reagent produces a hydrolyzed compound by leukocyte esterase, and the second reagent reacts with the hydrolyzed compound to show a color indicating the presence of leukocyte esterase.

Description

Nanofibrous membrane for the diagnosis of urinary tract infection including two types of nanofibers and a method for manufacturing the same}

The present invention relates to a nanofiber membrane for diagnosing urinary tract infection comprising two types of nanofibers and a method for manufacturing the same.

Urinary tract infection is a bacterial disease common in childhood, which means a bacterial infection in the urethra, bladder and kidneys. Urinary tract infections are accompanied by fever and pain. However, it is difficult for infants or the elderly, who have difficulty communicating, to notify their parents of symptoms of urinary tract infection. In addition, the symptoms of urinary tract infection are similar to those of the cold, so it is difficult for the guardian to know the patient's urinary tract infection. For this reason, infants or the elderly often visit hospitals after urinary tract infection has progressed significantly. Therefore, in order to prevent this, there is an inconvenience in that the guardian must continuously observe the victim and be diagnosed by visiting the hospital frequently.

In general, urinary tract infection is diagnosed by urine test through urine sample and urine culture test. Of these, urine testing is one of the simplest and fastest ways to diagnose urinary tract infections. In the diagnosis of urinary tract infection by urine test, a diagnostic kit that can be easily visually examined by changing the color in response to leukocyte esterase in urine is generally used.

However, urine testing requires a sample of the patient's urine. Infants, the elderly, and patients with mobility discomfort are difficult to provide urine samples themselves, and thus, there is a discomfort that requires the help of a guardian. There is also the inconvenience of visiting the hospital and providing samples. Therefore, a quick and simple urinary tract infection diagnosis means is required to solve the above problems.

Electrospinning is a means to produce fibers and fiber membranes in the nanometer range. Electrospinning has the advantage that it can be made of fibers using materials that were difficult to produce with fibers using conventional fiber manufacturing methods, and can also be made into non-woven fabrics.

Electrospinning can produce nanometer diameter fibers by releasing a polymer solution through a spinneret (or may also be referred to as a nozzle) on a high voltage. When a high voltage electric field is applied to the polymer solution of the spinneret, the positively charged polymer solution is discharged from the spinneret and collects in the negatively charged current collector. The polymer solution of the spinneret is in equilibrium between gravity and surface tension and forms hemispherical droplets. When an electric field is applied, electric charges are induced on the surface of the hemispherical droplets, and repulsion of electric charges creates a force opposite to the surface tension (Taylor cone formation). When a specific voltage is applied, a single jet is formed from the polymer solution, and the evaporation of the solvent may split into several fibers having a nanometer diameter. The split fibers may be irregularly collected in a negatively charged current collector to form a nonwoven fabric.

Electrospinning is known to be easy to produce functional fibers. As a method of manufacturing a functional fiber, a method of manufacturing a polymer solution containing a functional material by spinning is known. It is known that fabrication of functional fibers by electrospinning can produce thin diameter fibers and contain fewer reagents. However, the polymer solution containing the functional material has a problem that cutting occurs during spinning if the conditions are not appropriate.

Korean Registered Patent Publication No. 10-2011-0018114 (2011.02.23)

According to an embodiment of the present invention, there is provided a method of manufacturing a nanofibrous membrane for urinary tract infection diagnosis capable of diagnosing urinary tract infection.

According to an embodiment of the present invention, there is provided a method of manufacturing a nanofibrous membrane for urinary tract infection diagnosis in which no cutting occurs when electrospinning occurs.

According to an embodiment of the present invention, there is provided a method of manufacturing a nanofibrous membrane for diagnosing urinary tract infection that contains less reagent for diagnosing urinary tract infection.

According to an embodiment of the present invention provides a nanofibrous membrane for urinary tract infection diagnosis that can diagnose urinary tract infection.

According to an embodiment of the present invention, a nanofiber membrane for diagnosing a urinary tract infection having a thin thickness is provided.

According to an embodiment of the present invention provides a nanofibrous membrane for diagnosing urinary tract infection containing less reagent for diagnosing urinary tract infection.

The nanofibrous membrane for urinary tract infection diagnosis according to an embodiment of the present invention includes irregularly arranged nanofibers, and the nanofibers include a first nanofiber including only the first reagent and a second nanofiber including only the second reagent And, the first reagent generates a hydrolyzed compound by leukocyte esterase, and the second reagent reacts with the hydrolyzed compound to exhibit a color indicating the presence of leukocyte esterase.

The nano-fiber membrane for diagnosing urinary tract infection according to an embodiment of the present invention further includes a diffusion barrier layer laminated on the nanofiber membrane for diagnosing urinary tract infection.

The apparatus for diagnosing urinary tract infection according to an embodiment of the present invention includes the nanofibrous membrane for diagnosing urinary tract infection.

The method for preparing a nanofibrous membrane for urinary tract infection diagnosis according to an embodiment of the present invention comprises preparing a first polymer solution containing a first reagent that reacts with leukocyte esterase to generate a hydrolyzed compound, and reacts with the hydrolyzed compound Preparing a second polymer solution comprising a second reagent that indicates a color indicating the presence of leukocyte esterase, and simultaneously electrospinning the first polymer solution and the second polymer solution into one current collector. Includes.

The method of manufacturing a nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention may contain a reagent for diagnosing urinary tract infection when electrospinning, but may not cause truncation.

The nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention can visually confirm urinary tract infection.

The nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention may contain less reagent for diagnosing urinary tract infection.

The nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention may have a thin thickness and minimize the increase in volume when attached to a hygiene product.

The nanofibrous membrane for urinary tract infection diagnosis according to an embodiment of the present invention may improve the accuracy of urinary tract infection confirmation.

The nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention may be flexible, and may be easily applied to sanitary products whose shape needs to be changed according to movement.

1 shows an SEM photograph of a nanofiber membrane according to an embodiment of the present invention.
2 is a first reagent according to an embodiment of the present invention, for the description of the nano-fiber structure is a representation of the first reagent 10 in a spherical shape.
3 is in the second reagent according to an embodiment of the present invention, for the description of the nano-fiber structure, the second reagent 20 is represented by a cube.
4 illustrates a first nanofiber 100 including a first reagent 10 according to an embodiment of the present invention.
5 illustrates a second nanofiber 200 including a second reagent 20 according to an embodiment of the present invention.
6 is a view showing some structures of a nanofiber membrane in which the first nanofiber 100 and the second nanofiber 200 are irregularly arranged according to an embodiment of the present invention.
Figure 7 shows the step of electrospinning in the manufacture of a nanofibrous membrane for urinary tract infection diagnosis according to an embodiment of the present invention. Nozzle for component A is the first polymer solution, Nozzle for component B is the second polymer solution, and the Rotating Drum for Fiber Collection Target is an example of a current collector as a rotating current collector.

The nanofibrous membrane for urinary tract infection diagnosis according to an embodiment of the present invention includes irregularly arranged nanofibers, and the nanofibers include a first nanofiber including a first reagent and a second nanofiber including a second reagent And, the first reagent generates a hydrolyzed compound by leukocyte esterase, and the second reagent reacts with the hydrolyzed compound to exhibit a color indicating the presence of leukocyte esterase.

The nanofibrous membrane for diagnosing urinary tract infection may be a porous structure formed by irregularly arranging and accumulating nanofibers, for example, a structure similar to a nonwoven fabric.

Referring to FIG. 1, the nanofibrous membrane for diagnosing urinary tract infection forms a porous structure such as a nonwoven fabric by arranging nanofibers irregularly. Since the nano-fiber membrane has a thin thickness, it may be advantageous for thinning or miniaturization of a urinary tract infection diagnosis apparatus or hygiene product. In addition, the nanofibrous membrane for diagnosing urinary tract infection may have a large surface area by having a porous structure, and may easily absorb liquid or react with the liquid.

2 and 4, the sphere represents the first reagent 10, and the cylinder containing the sphere represents the structure of the first nanofiber 100 containing the first reagent. The first reagent 10 is included in the surface and the inside of the first nanofiber 100, and more specifically, may be carried or inclusion on the first nanofiber. The supported or enclosed structure may be formed by electrospinning a solution containing a first reagent and a polymer material.

3 and 5, the cube represents the second reagent 20, and the cylinder containing the cube represents the structure of the second nanofiber 200 containing the second reagent. The second reagent 20 is included in the surface and inside of the second nanofiber 200, and more specifically, may be carried or inclusion in the second nanofiber. The support or inclusion may be formed by electrospinning a solution containing a second reagent and a polymer material.

Referring to FIG. 6, the first nanofiber 100 and the second nanofiber 200 are arranged in an irregular arrangement to show a part of the nanofiber membrane having a porous non-woven structure. The structure such as the non-woven fabric may be formed by electrospinning the first nanofibers and the second nanofibers, and more specifically, may sequentially or simultaneously electrospin the first nanofibers and the second nanofibers. The first reagent and the second reagent are active ingredients of the urinary tract infection diagnostic reagent. The first reagent may include only the first reagent among the active ingredients of the urinary tract infection diagnostic reagent, and the second reagent may include only the second reagent among the active ingredients of the urinary tract infection diagnostic reagent.

The first reagent is to generate a hydrolysis compound by leukocyte esterase, and the hydrolysis compound may be an aromatic compound.

The first reagent may include at least one of indole acetate or naphtol AS-D chloroacetate (3-Hydroxy-2-naphthoic-o-toluidide chloroacetate as IUPAC name). The indole acetate and the naphthol acetone chloroacetate may react with a white blood cell esterase to generate a hydrolysis compound. The indole acetate is indoxyl acetate, indoxyl butyrate, indoxyl laurate, indoxyl stearate, indoxyl esters of N-blocking amino acids or peptides, lactate esters, indole carboxylic acid esters or methyl indole-3-carboxylate. And may include at least one.

The second reagent may include a diazonium salt. The diazonium salt may generate a dye material (azole-based dye) exhibiting color by reacting with the hydrolysis compound generated by the first reagent reacting with leukocyte esterase. The diazonium salt may be, for example, 1-diazo-2-naphthol-4-sulfonate; 1-diazophenyl-3-carbonate, 4-diazo-3-hydroxy-1-naphthylsulfonate (DNSA), 4-diazo-3-hydroxy-7-nitro-1-naphthyl Sulfonate (NDNSA), 4-diazo-3-hydroxy-1,7-naphthyldisulfonate, 2-methoxy-4-(N-morpholinyl)benzene diazonium chloride, 4-diazo-3 -Hydroxy-7-bromo-1-naphthylsulfonate and 4-diazo-3-hydroxy-7-[1,oxopropyl]-1-naphthylsulfonate, 5-chloro-2-methoxy Benzenediazonium chloride, or 2-chloro-4-benzamido-5-methylbenzenediazonium, and may include at least one of them.

The first reagent and the second reagent can detect leukocyte esterase present in urine. When a patient's bladder or urinary tract is infected, the number of leukocytes increases at the site of infection, so urinary tract infection can be diagnosed by detecting leukocyte esterase present in the urine.

In the case of the indole carboxylic acid ester, indoxyl is generated by leukocyte esterase, and the indoxyl reacts with a diazonium salt to produce a purple azole dye. In the case of the naphthol A.S. chloroacetate, it reacts with leukocyte esterase to produce a hydrolysis product, and the hydrolysis product reacts with a diazonium salt to produce a purple azole dye.

The nanofiber may include a water-soluble polymer material. The polymer material may be dissolved in a solvent to prepare an electrospinning solution, and when the electrospinning solution is electrospun, a material in the form of fibers such as short fibers or long fibers (filaments) may be manufactured. The water-soluble polymer material can have a faster chemical reaction with urine when compared to the water-insoluble polymer material. The water-soluble polymer material may be, for example, polyethylene oxide (PEO), polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) and polyvinyl alcohol (PVA), preferably polyethylene Oxide.

The molecular weight (Mw) of the polymer material may be 600,000 to 1,100,000 Mw, 700,000 to 1,000,000 Mw, 800,000 to 950,000 Mw, or 800,000 to 900,000 Mw. When the molecular weight of the polymer material is higher than the above range, the viscosity of the polymer solution increases, so the diameter of the nanofibers increases and the reagent may be difficult to diffuse evenly. If the molecular weight of the polymer material is lower than the above range, the diameter of the nanofibers may be too small, and it may be difficult to uniformly manufacture the diameter of the nanofibers.

The first nanofiber is 0.1 to 8%, 0.5 to 8%, 1.0 to 8%, 1.5 to 8%, 2.0 to 8%, 2.5 to 8% of the first reagent based on the total weight of the first nanofiber, 3.0 to 8%, 0.1 to 7%, 0.5 to 7%, 1.0 to 7%, 1.5 to 7%, 2.0 to 7%, 2.5 to 7%, 3.0 to 7%, 0.1 to 6%, 0.5 to 6%, 1.0 to 6%, 1.5 to 6%, 2.0 to 6%, 2.5 to 6%, or 3.0 to 6%, and the second nanofiber is the second reagent based on the total weight of the second nanofiber 0.1 to 8%, 0.5 to 8%, 1.0 to 8%, 1.5 to 8%, 2.0 to 8%, 2.5 to 8%, 3.0 to 8%, 0.1 to 7%, 0.5 to 7%, 1.0 to 7% , 1.5 to 7%, 2.0 to 7%, 2.5 to 7%, 3.0 to 7%, 0.1 to 6%, 0.5 to 6%, 1.0 to 6%, 1.5 to 6%, 2.0 to 6%, 2.5 to 6% , Or 3.0 to 6%. If the content of the reagent is too large, electrospinning may not be smooth due to truncation, and if the content of the reagent is too small, it may be difficult to diagnose urinary tract infection.

The ratio of the first nanofiber and the second nanofiber (first nanofiber/second nanofiber) included in the nanofiber membrane may be 0.5 to 1.2 or 0.9 to 1.1 based on weight, and preferably 0.95 to 1.05 Can be

The ratio of the first reagent and the second reagent included in the nanofiber membrane may be 1:2 to 2:1 based on weight.

The nanofibers may have a diameter of 50 to 1500 nm, 150 to 1400 nm, 250 to 1300 nm, 250 to 1200 nm, or 300 to 1100 nm.

The nanofiber membrane may have a porosity of 70 to 95%, 80 to 95%, or 85 to 95%. If the porosity is too low, the urine may not be absorbed sufficiently, and the contact area between the urine and the first reagent and the second reagent may be insufficient, and thus the sensitivity of the test may be weakened.

The nanofibrous membrane for diagnosing urinary tract infection may further include a first layer including the first nanofiber and the second nanofiber and a diffusion barrier layer laminated on the first layer.

The diffusion barrier layer is not particularly limited in kind and lamination method as long as the first reagent can limit the diffusion of the hydrolyzed compound generated by reacting with the leukocyte esterase. The diffusion barrier may be, for example, a polymer solution containing no reagents, which is laminated by electrospinning on the nanofibrous membrane for diagnosing urinary tract infection. The diffusion barrier can inhibit the diffusion of the hydrolysis compound generated by the reaction of the white blood cell esterase and the first reagent, and when applied to hygiene products such as diapers, suppress diffusion toward the skin side to minimize the effect on the human body. can do. For example, the water-soluble polymer is in the form of a gel when it comes into contact with urine, and the diffusion barrier can block the gel from directly contacting the skin.

In addition, the diffusion barrier layer may increase the reaction efficiency of the hydrolyzed compound and the second reagent by allowing the hydrolyzed compound not to diffuse indiscriminately and staying near the first layer and positioned close to the second reagent. When the efficiency of the reaction between the hydrolyzed compound and the second reagent is increased, more colored compounds are generated, and the color may be more vivid, and it may be easy to visually observe urinary tract infection.

The apparatus for diagnosing urinary tract infection according to an embodiment of the present invention includes the nanofibrous membrane for diagnosing urinary tract infection. The apparatus for diagnosing urinary tract infection has various advantages by including the nanofibrous membrane for diagnosing urinary tract infection. First, the urinary tract infection can be confirmed with the naked eye, so it can be diagnosed without visiting a hospital. In addition, the guardian can easily identify the urinary tract infection of the protected person. The apparatus for diagnosing urinary tract infection is not particularly limited as long as the nanofibrous membrane for diagnosing urinary tract infection can be applied, and may be, for example, a hygiene product such as a diagnostic sheet or a diaper. In concentrated urine, false positives may appear, and when a reducing agent such as vitamin C is present, false negatives may appear. .

The method for preparing a nanofibrous membrane for urinary tract infection diagnosis according to an embodiment of the present invention comprises preparing a first polymer solution containing a first reagent that reacts with leukocyte esterase to generate a hydrolyzed compound, and reacts with the hydrolyzed compound Preparing a second polymer solution comprising a second reagent that indicates a color indicating the presence of leukocyte esterase, and electrospinning the first polymer solution and the second polymer solution into one current collector. do.

Referring to FIG. 7, a process of electrospinning the first polymer solution (Nozzle for component A) and the second polymer solution (Nozzle for component B) to a rotating current collector (Rotating Drum for Fiber Collection Target) is illustrated. will be. The current collector may be any current collector known in the art to which the present invention pertains, and is not particularly limited to a rotating current collector.

In the electrospinning step, the first polymer solution and the second polymer solution may be sequentially electrospun, and preferably electrospin at the same time.

The current collector means a place where fibers formed by discharging a positively charged polymer solution from a spinneret are gathered, and may also be referred to as a collector or a collecting plate. The current collector may be negatively charged or grounded. The current collector is not particularly limited in shape, but may be in the form of a rotating drum.

The electrospinning may be electrospinning using a commercial mass production device, and more specifically, may be electrospinning to a device including a conveyor belt and a plurality of nozzles.

The solute content of the first polymer solution is 1 to 10% by weight, 2 to 10% by weight, 3 to 10% by weight, 4 to 10% by weight, 5 to 10% by weight, 6 to 6% by weight of the total weight of the first polymer solution 10%, 7-10%, 8-10%, 9-10%, 1-9%, 2-9%, 3-9%, 4-9%, 5-9% %, 6 to 9%, 7 to 9%, 8 to 9%, 1 to 8%, 2 to 8%, 3 to 8%, 4 to 8%, 5 to 8%, 6 to 8 wt%, 7 to 8 wt%, 1 to 7 wt%, 2 to 7 wt%, 3 to 7 wt%, 4 to 7 wt%, 5 to 7 wt%, 6 to 7 wt%, 1 to 6 wt%, 2-6 wt%, 3-6 wt%, 4-6 wt%, 5-6 wt%, 1-5 wt%, 2-5 wt%, 3-5 wt%, 4-5 wt% %, 1 to 4% by weight, 2 to 4% by weight, 3 to 4% by weight, 1 to 3% by weight, 2 to 3% by weight, or 1 to 2% by weight. In electrospinning the first polymer solution, if the content of the solute is outside the above range, drying of the solvent may not be smooth, or truncation may occur.

The solute content of the second polymer solution is 1 to 10% by weight, 2 to 10% by weight, 3 to 10% by weight, 4 to 10% by weight, 5 to 10% by weight, 6 to 6% by weight of the total weight of the second polymer solution 10%, 7-10%, 8-10%, 9-10%, 1-9%, 2-9%, 3-9%, 4-9%, 5-9% %, 6 to 9%, 7 to 9%, 8 to 9%, 1 to 8%, 2 to 8%, 3 to 8%, 4 to 8%, 5 to 8%, 6 to 8 wt%, 7 to 8 wt%, 1 to 7 wt%, 2 to 7 wt%, 3 to 7 wt%, 4 to 7 wt%, 5 to 7 wt%, 6 to 7 wt%, 1 to 6 wt%, 2-6 wt%, 3-6 wt%, 4-6 wt%, 5-6 wt%, 1-5 wt%, 2-5 wt%, 3-5 wt%, 4-5 wt% %, 1 to 4% by weight, 2 to 4% by weight, 3 to 4% by weight, 1 to 3% by weight, 2 to 3% by weight, or 1 to 2% by weight. In electrospinning the second polymer solution, if the content of the solute is outside the above range, drying of the solvent may not be smooth, or truncation may occur.

The first polymer solution may include the first reagent and a polymer material as a solute, and the first reagent is 0.1 to 8% by weight, 0.5 to 8% by weight, and 1.5 to 8% by weight based on the weight of the solute. , 2.0-8 wt%, 0.1-7 wt%, 0.5-7 wt%, 1.0-7 wt%, 1.5-7 wt%, 2.0-7 wt%, 0.1-6 wt%, 0.5-6 wt%, 1.5 It may be from 6 to 6% by weight, or from 2.0 to 6% by weight, the second polymer solution may include the second reagent and the polymer material as a solute, and the second reagent is 0.1 to 0.1 based on the weight of the solute. 8 wt%, 0.5-8 wt%, 1.5-8 wt%, 2.0-8 wt%, 0.1-7 wt%, 0.5-7 wt%, 1.0-7 wt%, 1.5-7 wt%, 2.0-7 wt% %, 0.1 to 6% by weight, 0.5 to 6% by weight, 1.5 to 6% by weight, or 2.0 to 6% by weight.

The first reagent may include at least one of indole acetate or Naphtol AS-D chloroacetate. The first reagent and indole acetate are the same as described above.

The second reagent may include a diazonium salt. The second reagent and diazonium salt are the same as described above.

The polymer material may be water-soluble. The water-soluble polymer material is the same as described above.

In the electrospinning step, the electrospinning conditions include flow rates of 0.5 to 1.5 ml/h, 0.6 to 1.5 ml/h, 0.7 to 1.5 ml/h, 0.8 to 1.5 ml/h, 0.9 to 1.5 ml/h, 1.0 to 1.5 ml/h, 0.5-1.4 ml/h, 0.6-1.4 ml/h, 0.7-1.4 ml/h, 0.8-1.4 ml/h, 0.9-1.4 ml/h, 1.0-1.4 ml/h, 1.1-1.4 ml /h, 1.2 to 1.4ml/h, 1.3 to 1.4ml/h, 0.5 to 1.3ml/h, 0.6 to 1.3ml/h, 0.7 to 1.3ml/h, 0.8 to 1.3ml/h, 0.9 to 1.3ml/h h, 1.0 to 1.3 ml/h, 1.1 to 1.3 ml/h, 1.2 to 1.3 ml/h, 0.5 to 1.2 ml/h, 0.6 to 1.2 ml/h, 0.7 to 1.2 ml/h, 0.8 to 1.2 ml/h , 0.9 to 1.2 ml/h, 1.0 to 1.2 ml/h, 1.1 to 1.2 ml/h, 0.5 to 1.1 ml/h, 0.6 to 1.1 ml/h, 0.7 to 1.1 ml/h, 0.8 to 1.1 ml/h, 0.9 to 1.1 ml/h, 1.0 to 1.1 ml/h, 0.5 to 1.0 ml/h, 0.6 to 1.0 ml/h, 0.7 to 1.0 ml/h, 0.8 to 1.0 ml/h, or 0.9 to 1.0 ml/h days You can. If the flow rate of the solution is too low, the electrostatic density increases and the viscosity of the spinning solution becomes relatively lower than the surface tension, so the diameter of the fiber may decrease. If the flow rate of the solution is too high, the electrostatic density may decrease and the diameter of the fiber may increase.

In the electrospinning step, the voltage for the electrospinning is 5 to 20 KV, 8 to 20 KV, 10 to 20 KV, 5 to 15 KV, 8 to 15 KV, 10 to 15 KV, 5 to 12 KV, 8 to 12 KV, or 10 to 12 KV. Can be If the voltage is too high, the radiation proceeds too quickly, which may cause the solvent to not volatilize. If the voltage is too low, the radiation may not proceed smoothly.

In the electrospinning step, the electrospinning conditions include a radiation distance of 8.0 to 12.0 cm, 9.0 to 12.0 cm, 10.0 to 12.0 cm, 11.0 to 12.0 cm, 8.0 to 11.0 cm, 9.0 to 11.0 cm, 10.0 to 11.0 cm, 8.0 to 10.0 cm, or 9.0 to 10.0 cm.

Radiation distance refers to the distance between a spinneret (which may also be referred to as a nozzle or tip) and a collector.

If the TIP to Collector Distance (TCD) is too short, the solvent may reach the current collector in a state where the solvent is not volatilized and the fiber may be larger than a desired diameter or beads may be formed. If the radiation distance is too long, the electric field is weak and radiation cannot be properly performed.

Hereinafter will be described in more detail through an embodiment of the present invention. However, these examples are for illustrative purposes only, and the present invention is not limited to the following examples.

<Example: Preparation of a fiber membrane for diagnosing urinary tract infection in which the first nanofiber and the second nanofiber are mixed>

1. Preparation of the first polymer solution

The composition ratio of the first polymer solution is 8% by weight of the first solute and 92% by weight of water based on the total weight of the first electrospinning solution.

The first solute is 97.5% by weight of the polymer material PEO (average Mw 900,000) based on the total weight of the first solute and 2.5% by weight of the first reagent, Naphthol AS-D chloroacetate.

It was mixed according to the composition ratio of the first polymer solution.

First, water and PEO (Polyethylene Oxide) were stirred with a magnetic stirrer for about 12 hours, the first reagent was added, and the mixture was further stirred for 3 hours to prepare a first polymer solution.

2. Preparation of the second polymer solution

The composition ratio of the second polymer solution is 5% by weight of the second solute and 95% by weight of water based on the total weight of the second polymer solution.

The second solute is 95% by weight of PEO (average Mw 900,000), a polymer material, based on the total weight of the second solute, and 5% by weight of the second reagent, 2-chloro-4-benzamido-2-methylbenzenediazonium. .

2-Chloro-4-benzamido-2-methylbenzenediazonium and water were mixed according to the composition ratio of the second polymer solution.

Mixing and stirring were performed in the same manner as in preparing the first polymer solution to prepare a second polymer solution.

3. Electrospinning

5 ml of the first polymer solution was loaded into the first syringe.

5 ml of the second polymer solution was loaded into the second syringe.

The first syringe and the second syringe were respectively prepared to be electrospinned independently, and simultaneously electrospinned into one current collector.

The conditions for electrospinning are 1 ml/h flow rate, voltage 10 KV, and tip to collector distance (TCD) 10 cm. The spinneret uses a G18 needle and has a diameter of 1 mm. The angle of the two spinnerets is about 45 degrees based on the radial direction.

As a result of simultaneous electrospinning under the above conditions, the solvent evaporated smoothly during electrospinning. A dried fiber membrane including the first nanofiber and the second nanofiber was left in the current collector.

<Experimental Example 1: Confirmation of composition ratio>

The composition ratio of the fibrous membrane for diagnosing urinary tract infection of Example 1 in which all the solvent was evaporated was measured.

The first nanofiber is 2.5 wt% of naphthol acetic acid chloroacetate and 97.5 wt% of PEO based on the total weight of the fiber membrane.

The second nanofiber is 5% by weight of 2-chloro-4-benzamido-2-methylbenzenediazonium chloride and 95.0% by weight of PEO based on the total weight of the fiber membrane.

<Experimental Example 2: Fiber membrane structure for urinary tract infection diagnosis>

The structure of the nanofibrous membrane for urinary tract infection prepared in Example was measured by SEM. Measurement conditions are WD 15.9mm, 15.0kv, x10K.

Referring to FIG. 1, the nanofiber membrane has a porous structure in which first nanofibers and second nanofibers are entangled, and the porosity is about 90%. The diameters of the first nanofibers and the second nanofibers are about 300 to 1000 nm, and on average, 500 nm.

10: first reagent
20: second reagent
100: first nanofiber
200: second nanofiber

Claims (14)

Containing nanofibers arranged irregularly,
The nanofibers include a first nanofiber comprising a first reagent and a second nanofiber comprising a second reagent,
The first reagent generates a hydrolysis compound by leukocyte esterase,
The second reagent reacts with the hydrolyzed compound to exhibit a color indicating the presence of leukocyte esterase,
Nanofibrous membrane for urinary tract infection diagnosis.
According to claim 1,
The first reagent comprises at least one of indole acetate or Naphtol AS-D chloroacetate
Nanofibrous membrane for urinary tract infection diagnosis.
According to claim 1,
The second reagent comprises a diazonium salt,
Nanofibrous membrane for urinary tract infection diagnosis.
According to claim 1,
The nanofiber comprises a water-soluble polymer material,
Nanofibrous membrane for urinary tract infection diagnosis.
According to claim 1,
The first nanofiber contains 0.1 to 6% of the first reagent based on the total weight of the first nanofiber,
The second nanofiber comprises 0.1 to 6% of the second reagent based on the total weight of the second nanofiber,
Nanofibrous membrane for urinary tract infection diagnosis.
According to claim 1,
The nanofibers are 50 to 1500 nm in diameter,
Nanofibrous membrane for urinary tract infection diagnosis.
According to claim 1,
The nano-fiber membrane has a porosity of 80 to 95%
Nanofibrous membrane for urinary tract infection diagnosis.
The method of claim 1.
A first layer comprising the first nanofiber and the second nanofiber; And
Further comprising a diffusion barrier layer laminated on the first layer,
Nanofibrous membrane for urinary tract infection diagnosis.
A device for diagnosing urinary tract infection comprising the nanofibrous membrane for diagnosing urinary tract infection according to claim 1.
Preparing a first polymer solution comprising a first reagent that reacts with leukocyte esterase to produce a hydrolyzed compound;
Preparing a second polymer solution comprising a second reagent that exhibits a color indicative of the presence of leukocyte esterase by reacting with the hydrolyzed compound; And
Electrospinning the first polymer solution and the second polymer solution to one current collector,
Method for manufacturing nanofibrous membrane for diagnosing urinary tract infection.
The method of claim 10,
The first polymer solution contains the first reagent and a polymer material as a solute, and the first reagent is 0.1 to 6% by weight based on the weight of the solute,
The second polymer solution contains the second reagent and a polymer material as a solute, and the second reagent is 0.1 to 6% by weight based on the weight of the solute.
Method for manufacturing nanofibrous membrane for diagnosing urinary tract infection.
The method of claim 10,
The first reagent comprises at least one of indole acetate or Naphtol AS-D chloroacetate,
Method for manufacturing nanofibrous membrane for urinary tract infection diagnosis.
The method of claim 10,
The second reagent comprises a diazonium salt,
Method for manufacturing nanofibrous membrane for urinary tract infection diagnosis.
The method of claim 10,
The polymer material is water-soluble,
Method for manufacturing nanofibrous membrane for urinary tract infection diagnosis.

Images